Brokerages Expect Dynavax Technologies Co. (DVAX) Will Post Earnings of -$0.58 Per Share
Equities analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to report earnings per share of ($0.58) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dynavax Technologies’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.60). Dynavax Technologies posted earnings of ($0.38) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 52.6%. The business is scheduled to report its next quarterly earnings report on Friday, November 2nd.
On average, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.33). For the next year, analysts anticipate that the business will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.01). Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The business had revenue of $1.25 million during the quarter, compared to analyst estimates of $1.88 million. During the same period in the previous year, the company earned ($0.41) earnings per share. The business’s revenue for the quarter was up 1094.3% on a year-over-year basis.
In other news, insider Michael S. Ostrach sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $15.53, for a total value of $62,120.00. Following the completion of the sale, the insider now directly owns 80,554 shares in the company, valued at approximately $1,251,003.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.47% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its holdings in shares of Dynavax Technologies by 9.2% in the 1st quarter. Wells Fargo & Company MN now owns 45,516 shares of the biopharmaceutical company’s stock valued at $903,000 after acquiring an additional 3,834 shares during the last quarter. Swiss National Bank increased its holdings in shares of Dynavax Technologies by 4.3% in the 1st quarter. Swiss National Bank now owns 104,178 shares of the biopharmaceutical company’s stock valued at $2,068,000 after acquiring an additional 4,300 shares during the last quarter. Creative Planning increased its holdings in shares of Dynavax Technologies by 2.6% in the 2nd quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock valued at $3,585,000 after acquiring an additional 5,857 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Dynavax Technologies by 10.8% in the 1st quarter. New York State Common Retirement Fund now owns 65,700 shares of the biopharmaceutical company’s stock valued at $1,304,000 after acquiring an additional 6,400 shares during the last quarter. Finally, Guggenheim Capital LLC increased its holdings in shares of Dynavax Technologies by 7.2% in the 1st quarter. Guggenheim Capital LLC now owns 112,278 shares of the biopharmaceutical company’s stock valued at $2,228,000 after acquiring an additional 7,522 shares during the last quarter. Institutional investors and hedge funds own 78.57% of the company’s stock.
Shares of DVAX traded up $0.02 during trading on Friday, reaching $12.60. The company’s stock had a trading volume of 511,000 shares, compared to its average volume of 1,449,532. Dynavax Technologies has a twelve month low of $12.25 and a twelve month high of $24.45. The firm has a market cap of $832.79 million, a price-to-earnings ratio of -7.28 and a beta of 0.29. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Featured Story: Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.